UNITY Shares Nearly Halved after Lead Asset Fails to Match Regeneron’s Eylea

UNITY Biotechnology’s lead asset, UBX1325, failed to show non-inferiority to Regeneron’s blockbuster Eylea in a Phase II wet age-related macular degeneration trial.